Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.45 |
| ▸ | PDE8B | O95263 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060646 | 0.89 | TLR7 (0.48) | TLR7KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2060460 | 0.89 | ALDH1A1 (0.50) | TLR7KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2060432 | 0.88 | TSHR (0.46) | TLR7KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2060226 | 0.87 | TLR7 (0.43) | TLR7PDE8BKDM4EALDH1A1GAA | |
| SCHEMBL2060478 | 0.86 | TLR7 (0.53) | TLR7TSHR | |
| SCHEMBL2060248 | 0.85 | TLR7 (0.42) | TLR7KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2060146 | 0.84 | TLR7 (0.42) | TLR7PDE8BKDM4EALDH1A1GAA | |
| SCHEMBL2060484 | 0.84 | KDM4E (0.45) | TLR7KDM4EALDH1A1GAAHPGD | |
| SCHEMBL5464032 | 0.83 | TLR7 (0.47) | TLR7PDE8BKDM4EALDH1A1GAA | |
| SCHEMBL2060210 | 0.83 | TLR7 (0.56) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060052403-A1 | Novel adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1550662-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | TLR7 265/4885PDE8B 1754/4885KDM4E 2210/4885 |
| US-20060052403-A1 | Novel adenine compound and use thereof | ADORA1, P2RY10, HRH4 | TLR7 265/4885PDE8B 1754/4885KDM4E 2210/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | TLR7 252/4885PDE8B 1735/4885KDM4E 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.